Survodutide (10mg) Dosage Protocol
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist in clinical development by Boehringer Ingelheim. Phase 2 trials have shown significant weight loss and improvements in liver fat.
Add 2.0 mL bacteriostatic water → 5 mg/mL
0.6-4.8 mg once weekly (clinical trial doses)
At 5 mg/mL: 12 units = 0.6 mg, 96 units = 4.8 mg
Lyophilized: -20°C; Reconstituted: 2-8°C for up to 4 weeks
| Week | Daily Dose | Units (per injection) |
|---|---|---|
| Weeks 1-4 | 0.6 mg weekly | 12 units once weekly |
| Weeks 5-8 | 1.2-2.4 mg weekly | 24-48 units weekly |
| Weeks 9+ | 3.6-4.8 mg weekly | 72-96 units weekly |
- 1Draw 2.0 mL bacteriostatic water with a sterile syringe
- 2Inject slowly down the vial wall
- 3Gently swirl until fully dissolved - do not shake
- 4Label with date and concentration, refrigerate immediately
Survodutide activates GLP-1 receptors (appetite suppression, glycemic control) and glucagon receptors (increased energy expenditure, hepatic fat reduction). Phase 2 trials showed up to 19% weight loss at 46 weeks and significant reductions in liver fat content.
- Significant weight loss in trials
- Reduces liver fat content
- Dual mechanism of action
- Once weekly dosing convenience
- Boehringer Ingelheim Phase 2 trial data
- Survodutide clinical development program
- Dual agonist research for obesity and NASH
Lyophilized
Store at -20°C, protected from light
Reconstituted
Refrigerate at 2-8°C, use within 4 weeks
Slow titration essential for tolerability
- •Investigational compound - not yet approved
- •Phase 3 trials ongoing
- •GI side effects common during titration
- •Being studied for NASH/MASH
Disclaimer: This content is intended for research and educational purposes only. Not intended to diagnose, treat, cure, or prevent any disease. All compounds are for research use only. Dosing information is derived from published scientific literature and clinical studies.